Is ALNEV.PA undervalued or overvalued?

As of 2025-03-25, the Intrinsic Value of Neovacs SA (ALNEV.PA) is (7,068.81) EUR. This ALNEV.PA valuation is based on the model Discounted Cash Flows (Growth Exit 5Y). With the current market price of 0.05 EUR, the upside of Neovacs SA is -15,201,852.30%. This means that ALNEV.PA is overvalued by 15,201,852.30%.

The range of the Intrinsic Value is (26,309.69) - (4,195.65) EUR

Note: result may not be accurate due to the invalid valuation result of DCF model.

	Range	Selected	Upside
a
DCF (Growth 5y)	(26,309.69) - (4,195.65)	(7,068.81)	-15201852.3%
DCF (Growth 10y)	(3,497.42) - (20,103.50)	(5,654.67)	-12160673.5%
DCF (EBITDA 5y)	(240.87) - (232.36)	(1,234.50)	-123450.0%
DCF (EBITDA 10y)	(379.63) - (363.93)	(1,234.50)	-123450.0%
Fair Value	-656.50 - -656.50	-656.50	-1,411,938.70%
P/E	(1,885.49) - (3,356.07)	(2,652.29)	-5703949.3%
EV/EBITDA	563.91 - 688.44	599.49	1289133.9%
EPV	(2,549.18) - (2,519.87)	(2,534.53)	-5450693.4%
DDM - Stable	(607.27) - (1,626.09)	(1,116.68)	-2401565.6%
DDM - Multi	(147.20) - (331.38)	(206.45)	-444084.1%